Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
Purpose
This study will investigate the inflammatory response. People with abnormal regulation of
inflammation and immune defects often have an exaggerated or depressed inflammatory response
that results in poor healing of recurrent infections. This study will measure and compare
amounts of inflammatory mediators (chemicals involved in the inflammatory response) in
healthy normal volunteers and in patients with abnormal immune responses.
Healthy normal volunteers and patients with host defense defects or excessive inflammation,
as in vasculitis syndromes, may be eligible for this study. Patients must be between 6 and
65 years of age.
Participants will have eight small blisters raised on the forearm using a gentle suction
device. The top of the blisters will be removed with scissors and a plastic template will be
placed over the blisters. The wells of the template will be filled with a salt solution or a
mixture of the subject's serum (fluid part of the blood without cells) and a salt solution.
Some blisters may be covered with coverslips-a small round piece of very thin sterilized
glass-before adding the fluid. Blister fluid will be removed from the wells at 3, 5, 8, and
24 hours with a syringe and analyzed for inflammatory mediators. A scab will form over the
blisters and fall off in about 2 weeks.
Participants will have about 4 tablespoons of blood drawn in order to compare the
inflammatory mediators in the blood with those in the blister fluid.
Detailed Description
Patients with abnormal regulation of inflammation and with host defense defects often have
an exaggerated or depressed inflammatory response with resultant difficulty in healing of
recurrent infections. Delayed healing can be manifested by either a delay in wound healing,
granuloma formation along the incision line, or dehiscence of a partially healed wound
without evidence of infection. We are interested in studying the dynamics of host immune
defenses during an experimentally induced inflammatory response using a well-studied suction
blister device. This protocol is designed to study mediators of inflammation in patients
with host defense defects as well as patients with excessive inflammation as in the
vasculitis syndromes. We will measure mediators of inflammation (e.g., C5a, leukotriene B4,
interleukins, chemokines, tumor necrosis factor, interferon-gamma) by ELISA,
radioimmunoassay, High Performance Liquid Chromatography, multiplex cytokine assays, and/or
bioactivity assays. Furthermore, molecular characterization and host defense functions
(e.g., respiratory burst, chemotaxis, phagocytosis, microbicidal activity) of cells
recruited to the blisters will also be examined. In addition to the analysis of cell
function, RNA will be prepared and subject to DNA microarray or quantitative RT-PCR studies
to measure expression and dynamics of key inflammatory mediators. Many of these factors
contribute to the inflammatory process and several are thought to be important in granuloma
formation. If patients are found to have abnormal amounts of these mediators when compared
to normal volunteers or patients with other abnormalities it will help us understand the
basis for their disease and new therapeutic strategies. For example, this blister study
allowed us to identify a patient subsequently shown to have IRAK4 deficiency.
Eligibility
Ages Eligible for Study: 6 to 65
Genders Eligible for Study: Male & Female
Criteria:
- INCLUSION CRITERIA - PATIENTS:
Patients having or thought to have an immune defect between the ages of 6 and 65 years
(inclusive) are eligible to participate.
INCLUSION CRITERIA - NORMAL VOLUNTEERS:
Be a healthy adult of either sex and between the ages of 18 and 65 years old.
Weight greater than 110 pounds.
Not have any heart, lung, or kidney disease, or bleeding disorders.
Not have a history of viral hepatitis (B or C) since age 11.
Not have a history of intravenous injection drug use.
Not have a history of engaging in high-risk activities for exposure to the AIDS virus.
Not be pregnant.
EXCLUSION CRITERIA - PATIENTS:
Patients less than 6 or greater than 65 years of age.
EXCLUSION CRITERIA - NORMAL VOLUNTEER:
Less than 18 years old or older than 65 years.
Have viral hepatitis (B or C).
HIV positive.
Receiving chemotherapeutic agent(s), or have underlying malignancy.
Pregnant.
Have history of heart, lung, kidney disease, or bleeding disorders.

*ClinicalTrials.gov provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.